Abstract: 【Objective】 This study aimed to investigate the expression of CISD2 in early-stage cervical adenocarcinoma tissues and its association with the clinical features. 【Methods】 CISD2 expression was examined by immunohistochemical method in 56 cases of early-stage (FIGO stage IB-IIA) cervical adenocarcinoma tissues

and 3 cases of normal cervical tissues were used as negative control. Statistical analyses were performed to evaluate the association between CISD2 expression and the clinicopathological characteristics and prognosis of early-stage cervical adenocarcinoma. 【Results】 CISD2 expression was positive in early-stage (FIGO stage IB-IIA) cervical adenocarcinoma tissues: CISD2 high expression accounted for 44.6% and CISD2 low expression was 55.4%

but negative in normal cervical tissues. The level of CISD2 expression was significantly correlated with deep myometrium invasion (P =0.023)

lymph node metastasis (P = 0.003) and ovarian metastasis (P = 0.014). Patients with high CISD2 expression had a lower 5-year survival rate than patients with low CISD2 expression (P = 0.002). Multivariate analysis suggested that CISD2 expression was an independent prognostic marker for survival in patients with early-stage cervical adenocarcinoma (P = 0.027). 【Conclusion】 CISD2 expression was closely associated with clinical features and prognosis

and it might be a novel biomarker for the prediction of prognosis of early-stage cervical adenocarcinoma.